The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTeam17 Regulatory News (TM17)

Share Price Information for Team17 (TM17)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 275.00
Bid: 270.00
Ask: 280.00
Change: 2.00 (0.75%)
Spread: 10.00 (3.704%)
Open: 270.00
High: 267.00
Low: 267.00
Prev. Close: 265.00
TM17 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Options

7 Jul 2020 07:00

RNS Number : 1843S
Team17 Group PLC
07 July 2020
 

7 July 2020

Team17 Group plc

("Team17", the "Group" or the "Company")

 

Exercise of options and admission to trading

 

Team17, a global games entertainment label, creative partner and developer of independent ("indie") premium video games, announces that, further to the exercise of options as part of the Team17 Group plc Long Term Incentive Plan, it has issued and allotted, subject to admission to trading on AIM ("Admission"), 70,946 new ordinary shares of £0.01 each (the "New Ordinary Shares").

 

Application for admission of the New Ordinary Shares to trading on AIM has been made and dealings in the New Ordinary Shares are expected to commence at 8.00 a.m. on 10 July 2020. The New Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu with the existing ordinary shares of £0.01 each in the capital of the Group, including the right to receive all future dividends and distributions declared, made or paid by reference to a record date falling after their issue.

 

Total Voting Rights

Following admission of the 70,946 new ordinary shares, the Group's issued share capital will comprise 131,473,222 ordinary shares of £0.01 each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Group under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Enquiries:

 

Team17 Group plc

Debbie Bestwick MBE, Chief Executive Officer

Mark Crawford, Chief Financial Officer

 

via Vigo Communications

+44 (0)20 7390 0238

GCA Altium (Nominated Adviser)

Phil Adams / Adrian Reed / Paul Lines

 

+44 (0)845 505 4343

Berenberg (Broker)

Chris Bowman / Toby Flaux / Marie Moy / Alix Mecklenburg-Solodkoff

 

+44 (0)20 3207 7800

Vigo Communications (Financial Public Relations)

Jeremy Garcia / Charlie Neish

team17@vigocomms.com

+44 (0)20 7390 0238

 

 

About Team17

Team17 is a leading games entertainment label and creative partner for independent ("indie") developers, focused on the premium, rather than free to play market, and creating games for the PC home computer market, the video games console market and the mobile and tablet gaming markets. Alongside developing the Company's own games in house ("first party IP"), Team17 also partners with independent developers across the globe to add value to their games in all areas of development and production alongside bringing them to market across multiple platforms for fixed percentage royalties ("third-party IP"). Since foundation in 1990, we have launched over 100 games, including the iconic Worms franchise, the Overcooked franchise, the Escapists franchise, Yooka-Laylee, Yoku's Island Express, My Time at Portia, Hell Let Loose and Blasphemous, making Team17 one of the most prolific developers and partners of games for the indie market.

 

 Visit www.team17.com for more info.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEVQLFBBDLEBBV
Date   Source Headline
16th Apr 20247:00 amRNSUnaudited Final Results 2023
12th Apr 20241:16 pmRNSDirector/PDMR Shareholding
11th Apr 20247:00 amRNSNotice of Analyst & Investor Meetings, FY Results
19th Mar 20243:29 pmRNSHoldings in Company
13th Mar 20248:30 amRNSDirector/PDMR Shareholding
1st Mar 20248:58 amRNSNotice of Results
14th Feb 20241:00 pmRNSDirector/PDMR Shareholding
13th Feb 20244:28 pmRNSDirector/PDMR Shareholding
1st Feb 20241:10 pmRNSHolding(s) in Company
29th Jan 20247:00 amRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading Update
19th Jan 20243:01 pmRNSHolding(s) in Company
12th Jan 20244:53 pmRNSHolding(s) in Company
12th Jan 20243:04 pmRNSHolding(s) in Company
11th Jan 20243:23 pmRNSDirector/PDMR Shareholding
14th Dec 20239:15 amRNSDirector/PDMR Shareholding
28th Nov 20237:00 amRNSDirector Dealings
27th Nov 20237:00 amRNSDirector Dealings
24th Nov 20237:00 amRNSTrading Update
15th Nov 20233:29 pmRNSHolding(s) in Company
13th Nov 20234:57 pmRNSDirector/PDMR Shareholding
30th Oct 20233:51 pmRNSHolding(s) in Company
18th Oct 202312:41 pmRNSHolding(s) in Company
11th Oct 20235:14 pmRNSDirector/PDMR Shareholding
21st Sep 20231:06 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSHalf Year Results
12th Sep 20239:00 amRNSDirector/PDMR Shareholding
22nd Aug 20237:00 amRNSBoard Update
17th Aug 20234:46 pmRNSHolding(s) in Company
14th Aug 20239:00 amRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSNotice of Results & Trading Update
19th Jul 20237:00 amRNSDirectorate Changes
18th Jul 20232:15 pmRNSDirector/PDMR Shareholding
14th Jul 20237:00 amRNSAppointment of Joint Corporate Broker
12th Jul 20233:36 pmRNSDirector/PDMR Shareholding
22nd Jun 20232:01 pmRNSResult of AGM
16th Jun 20234:27 pmRNSHolding(s) in Company
14th Jun 20238:55 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSAppointment of Group Chief Executive Officer
26th May 20237:01 amRNSBoard Update
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
25th May 20234:42 pmRNSHolding(s) in Company
15th May 202312:50 pmRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSTeam17's astragon Acquires Independent Arts
13th Apr 20233:40 pmRNSIssue of Shares
12th Apr 20238:20 amRNSDirector/PDMR Shareholding
31st Mar 202311:15 amRNSDirector/PDMR Shareholding
28th Mar 20237:01 amRNSDirector Update
28th Mar 20237:00 amRNSUnaudited Final Results 2022
13th Mar 20234:49 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.